T-DXd Moves Into Curative Setting in HER2-Positive Breast Cancer

(MedPage Today) — The DESTINY-Breast11 (DB-11) and DESTINY-Breast05 (DB-05) trials, presented at the European Society for Medical Oncology (ESMO) congress, showed that the inclusion of neoadjuvant or adjuvant trastuzumab pathologic complete response…